First Look at Iza-bren in TNBC: Dr. Megan Kruse on Top ASCO26 Research

Dr. Megan Kruse of the Cleveland Clinic analyzes the results of the PANKU-Breast02 trial comparing izalontamab brengitecan versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer. Read the full abstract (LBA1003) from the 2026 ASCO Annual Meeting: https://www.asco.org/abstracts-presentations/259338 For more on ASCO26, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 6, 2026_

Video Lainnya